ImmunID, Cytheris commence CYT107 and XELODA Phase IIa trial in metastatic breast can

[News]

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

More... (http://www.news-medical.net/news/20110511/ImmunID-Cytheris-commence-CYT107-and-XELODA-Phase-IIa-trial-in-metastatic-breast-cancer.aspx)